https://www.selleckchem.com/pr....oducts/gpr84-antagon
92 (95% CI 0.75-1.12). The incidence of exacerbation on LAMA was significantly lower than on LABA (HR 0.88; 95% CI 0.80-0.96) among patients with a prior exacerbation, and the HR of exacerbation increased with percent predicted FEV1. This study in the real world clinical setting of COPD treatment found that using a LAMA or a LABA (no ICS) as the initial bronchodilator is generally as effective at reducing exacerbation incidence and frequency. However, a LAMA may be more effective in patients with prior exacerbations, which su
Curtir
Comentario
Compartilhar
